|View printer-friendly version|
|Array BioPharma Announces Compound Acquisition Agreements With Pfizer|
|BOULDER, Colo., Jan. 15 /PRNewswire-FirstCall/ -- Array BioPharma Inc.
(Nasdaq: ARRY) today announced that it signed a series of non-exclusive
agreements to provide Pfizer Inc. (NYSE: PFE) with chemical compounds from the
Array Discovery Platform for its internal drug discovery programs. Financial
details were not disclosed.
"We are delighted that a company of Pfizer's caliber chose to access the Array Discovery Platform," said David L. Snitman, Ph.D., Chief Operating Officer and Vice President of Business Development, Array BioPharma. "We anticipate that these series of agreements will position Pfizer as one of Array's top five collaborators for Fiscal Year 2002."
About the Array Discovery Platform:
Array's experienced scientists integrate the most advanced tools and technologies in chemistry, biology and informatics to efficiently create new small molecule therapeutics. The Array Discovery Platform is the preferred solution for today's leading pharmaceutical and biotechnology companies to turn genomics into tomorrow's breakthrough drugs.
About Array BioPharma:
Array BioPharma is a drug discovery company inventing new drugs through the integration of chemistry, biology and informatics. We collaborate with leading pharmaceutical and biotechnology companies to identify novel small molecule drugs using the Array Discovery Platform. We leverage this integrated approach to small molecule drug discovery to develop our own pipeline of proprietary drug candidates. For more information on Array BioPharma, please visit the company's web site at www.arraybiopharma.com .
Array Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed below and described more fully in reports filed by Array with the Securities and Exchange Commission, including our Annual Report on Form 10-K as filed on September 27, 2001. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to collaborate with third parties on their drug discovery activities, the ability of our collaborators and of Array to meet drug discovery objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of January 15, 2002. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
SOURCE Array BioPharma Inc.
CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, firstname.lastname@example.org